^
Association details:
| Biomarker: | CD38 positive |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Actinium-225 conjugated to daratumumab (Ionizing radiation emitter, CD38-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors
Excerpt:
CD38-positive lymphoma Daudi cell line and MM cell lines KMS-28BM and KMS-28PE were treated in vitro with 225Ac-daratumumab….225Ac-daratumumab efficiently and specifically killed CD38-positive tumor cells in vitro…Conjugation of daratumumab to 225Ac significantly increases its anti-tumor potency against Daudi and KSM28BM tumors in vivo.
DOI:
https://doi.org/10.1080/2162402X.2019.1607673
